Literature DB >> 3919398

Inactivation of interferon by serum and synovial fluids.

P O'Kelly, L Thomsen, J G Tilles, T Cesario.   

Abstract

The stability of interferons-alpha, -beta, and -gamma (IFN) in serum and synovial fluids were compared. Interferon-beta was the least stable interferon species, losing at least 75% of its activity during incubation in samples of both serum and synovial fluid. Interferon-alpha was the most stable IFN, but interferon-gamma under these conditions approached the stability of the alpha species. The inactivation of IFN-beta was found due to dialyzable factors and hence not classical antibodies.

Entities:  

Mesh：

Substances：

Year:  1985        PMID： 3919398     DOI： 10.3181/00379727-178-42024

Source DB:  PubMed          Journal:  Proc Soc Exp Biol Med        ISSN： 0037-9727


  4 in total

1.  In vivo levels and in vitro production of interferon-gamma in fibrosing interstitial lung diseases.

Authors:  C Prior; P L Haslam
Journal:  Clin Exp Immunol       Date:  1992-05       Impact factor: 4.330

2.  Prolonging the half-life of human interferon-alpha 2 in circulation: Design, preparation, and analysis of (2-sulfo-9-fluorenylmethoxycarbonyl)7- interferon-alpha 2.

Authors:  Y Shechter; L Preciado-Patt; G Schreiber; M Fridkin
Journal:  Proc Natl Acad Sci U S A       Date:  2001-01-30       Impact factor: 11.205

3.  Identification in synovial fluid of a new potential pathogenic player in arthropathies.

Authors:  Anna Scanu; Mariagrazia Lorenzin; Roberto Luisetto; Paola Galozzi; Augusta Ortolan; Francesca Oliviero; Andrea Doria; Roberta Ramonda
Journal:  Exp Biol Med (Maywood)       Date:  2022-04-26

4.  Type I interferon-dependent gene MxA in perinatal HIV-infected patients under antiretroviral therapy as marker for therapy failure and blood plasmacytoid dendritic cells depletion.

Authors:  Raffaele Badolato; Claudia Ghidini; Fabio Facchetti; Federico Serana; Alessandra Sottini; Marco Chiarini; Elena Spinelli; Silvia Lonardi; Alessandro Plebani; Luigi Caimi; Luisa Imberti
Journal:  J Transl Med       Date:  2008-09-09       Impact factor: 5.531
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.